US Patent 10626187 Antigen binding molecules specific for an anti-CD19 scFv
Patent 10626187 was granted and assigned to Kite Pharma, Inc. on April, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 11 Apr, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 8 Oct, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
106261870
Date of Patent
April 21, 2020
0Patent Application Number
157176910
Date Filed
September 27, 2017
0Official Website
Patent Citations Received
Patent Primary Examiner
Edits on 13 Jul, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10626187 Antigen binding molecules specific for an anti-CD19 scFv
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10626187
Date of patent
April 21, 2020
Patent application number
15717691
Date Filed
September 27, 2017
Patent primary examiner
Find more entities like US Patent 10626187 Antigen binding molecules specific for an anti-CD19 scFv
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
